The valuation of healthtech and medtech entities represents one of the most complex exercises in corporate finance, requiring analysts to bridge the gap between long-term scientific development, binary regulatory approvals, capital intensive commercialisation and rapid technological obsolescence. Within a discounted cash flow (DCF) model, the terminal value is the single most critical and sensitive component of a company's total implied valuation, typically constituting betwe

The global computing landscape is undergoing a structural realignment. Driven by the rapid scaling of generative artificial intelligence and deep learning, the historical trajectory toward centralised public cloud environments is being challenged by a highly optimised, decentralised paradigm. NVIDIA is at the forefront of this transition, promoting on-premises "AI Factories" and localised hardware architectures as the defining infrastructure for the next decade of technology

Here's what's moved in European HealthTech over the past week, with the sector's attention firmly on Amsterdam. On funding, the standout was Semble's £30M Series C, led by Revaia with Partech and Octopus Ventures, to expand its open, interoperable clinical platform into France and larger European groups. Around it, a cluster of smaller AI-led rounds: 01Health ($15M Series A, specialist healthcare infrastructure, UK),

Deep-tech health monitoring has emerged as a major point of convergence for consumer electronics and longevity science. A notable project in this landscape is Temple, a neuro-technology and biological monitoring startup founded in 2024 by Deepinder Goyal, the founder and executive chairman of the Indian consumer-internet giant Zomato.

Five thousand leaders, one in three of them holding an executive title, descended on the RAI Amsterdam from 15th to 18th June 2026 for HLTH Europe. The call to action this year was "Step Outside", a deliberate nudge to leave the comfort zone, look at familiar problems from unfamiliar angles, and find energy in collaboration across boundaries. For those of us who spend our days on the deal side of digital health, the phrase turned out to be an unusually accurate description of

The entry of Midjourney Inc. into the medical hardware sector represents a significant shift for a company previously known for subscription-based generative artificial intelligence software. Unveiled by Chief Executive Officer David Holz on June 17th 2026, under the newly formed "Midjourney Medical" division, the "Midjourney Scanner" is proposed as a full-body, high-throughput ultrasonic imaging system designed to capture a comprehensive three-dimensional map of internal hum

Tokenmaxxing emerged in early 2026 as a highly polarising workplace phenomenon within Silicon Valley engineering organisations. Defined as the deliberate maximisation of artificial intelligence token consumption, the practice was initially conceptualised by some management teams as a proxy metric for employee productivity and AI integration. The fundamental premise of tokenmaxxing is that higher token consumption correlates directly with greater utilisation of powerful AI cap

The global digital health sector is undergoing a structural realignment driven by the rapid integration of artificial intelligence, machine learning and large language models (LLMs). For over two decades, the valuation and operational viability of health information technologies were dictated by classic software-as-a-service (SaaS) unit economics. These legacy frameworks relied on highly predictable variables, primarily measured through customer lifetime value (LTV), customer

Nelson Advisors partner Lloyd Price has been interviewed by Healthcare Business International for their 'Sigma Healthcare drops out of talks to acquire Boots' story focused on the strategic M&A and IPO options available to Boots and their PE owners Sycamore Partners.

NHS ConfedExpo 2026 marked a decisive shift from abstract digital strategies to the pragmatic delivery of the NHS 10-Year Health Plan. The overwhelming consensus across Manchester’s exhibition halls last week was that the NHS can no longer simply "manage" its way through modern backlogs; it has to transform its way out.

The European healthcare technology and medical technology sectors have reached a definitive operational and financial inflection point. Following a period of post-pandemic recalibration, the transaction landscape has transitioned into an era of disciplined industrial maturity, widely characterised by market analysts as the "Great Rationalisation". The speculative business models of the early 2020s, which prioritised user acquisition and un-monetised top-line expansion, have b

The healthcare technology sector in 2026 has entered a structurally distinct phase of maturation, transitioning from the speculative, "growth-at-all-costs" venture capital paradigms of the early 2020s into a disciplined era defined by profitable efficiency, clinical validation and platform scale. Following several years of valuation corrections and capital constraints, global healthtech mergers and acquisitions (M&A) are accelerating rapidly. This resurgence is fueled by a ma

The artificial intelligence landscape has entered an aggressive, capital-fuelled deflationary cycle driven by intense competition among frontier model providers. Backed by monumental private financing rounds, including Anthropic's Series G funding at a $380 Billion post-money valuation and rapid algorithmic optimization, API pricing for frontier reasoning models has collapsed.

European HealthTech has seen a massive surge in specialised AI deployments and notable funding rounds this week, particularly focusing on optimising operational workflows, surgical intelligence and deep-tech medical solutions. The European MedTech sector has experienced a highly active week, marked by major growth funding, critical legislative pushback over AI medical regulations, and a substantial shift in the UK's regulatory framework to attract global hardware innovation.

Of the 113 global digital health exits recorded in the first half of 2025, 107 were executed through M&A transactions, whereas a mere 6 were achieved via public listings. This profound shift marks a permanent structural transition from a phase of speculative, venture-backed exuberance to one of pragmatic, highly disciplined growth.